These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34090807)

  • 41. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection.
    Zhang LP; Ren H; Du YX; Wang CF
    World J Gastroenterol; 2020 Dec; 26(46):7382-7404. PubMed ID: 33362391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of post-preoperative tumor markers increments in patients with non-metastatic gastric cancer.
    Zhu XD; Zhang LX; Luo PQ; Zhu H; Wei ZJ; Xu AM
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12191-12201. PubMed ID: 37430160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
    Xu P; Wang X; Qian J; Li Z; Yao J; Xu A
    Medicine (Baltimore); 2021 Feb; 100(6):e24651. PubMed ID: 33578593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Prognostic Relevance of Preoperative CEA and CA19-9 for Ampulla of Vater Carcinoma.
    Matsui S; Yamamoto Y; Okamura Y; Ito T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K; Sugiura T
    Anticancer Res; 2022 Jun; 42(6):3169-3176. PubMed ID: 35641260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma.
    Smith RA; Bosonnet L; Ghaneh P; Raraty M; Sutton R; Campbell F; Neoptolemos JP
    Dig Surg; 2008; 25(3):226-32. PubMed ID: 18577869
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carbohydrate antigen 19-9 as a novel prognostic biomarker in distal cholangiocarcinoma.
    Jiang T; Lyu SC; Zhou L; Wang J; Li H; He Q; Lang R
    World J Gastrointest Surg; 2021 Sep; 13(9):1025-1038. PubMed ID: 34621478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy.
    Yang HK; Park MS; Han K; Eom G; Chung YE; Choi JY; Bang S; Kang CM; Seong J; Kim MJ
    Cancer Res Treat; 2024 Jan; 56(1):247-258. PubMed ID: 37605535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio.
    Smith RA; Ghaneh P; Sutton R; Raraty M; Campbell F; Neoptolemos JP
    J Gastrointest Surg; 2008 Aug; 12(8):1422-8. PubMed ID: 18543046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
    Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
    Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.
    Li Z; Zhu H; Pang X; Mao Y; Yi X; Li C; Lei M; Cheng X; Liang L; Wu J; Ding Y; Yang J; Sun Y; Zhang T; You D; Liu Z
    BMC Cancer; 2022 Sep; 22(1):962. PubMed ID: 36076189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
    Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
    La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
    World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer.
    Feng L; Gu S; Wang P; Chen H; Chen Z; Meng Z; Liu L
    Cancer Med; 2018 Dec; 7(12):5943-5951. PubMed ID: 30474926
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
    Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative definitions of pain, CA19-9, and tumor size as high-risk features of resectable pancreatic cancer: a single-center retrospective cohort study.
    Xu D; Wang J; Liu T; Huang Z; Luo J; Chen Y; Lu Y
    Gland Surg; 2021 Feb; 10(2):770-779. PubMed ID: 33708559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center analysis.
    Hu H; Qu C; Tang B; Liu W; Ma Y; Chen Y; Xie X; Zhuang Y; Gao H; Tian X; Yang Y
    Chin J Cancer Res; 2021 Aug; 33(4):457-469. PubMed ID: 34584371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative Alkaline Phosphatase-to-Cholesterol Ratio as a Predictor of Overall Survival in Pancreatic Ductal Adenocarcinoma Patients Undergoing Radical Pancreaticoduodenectomy.
    Qiu G; Zhang L; Gu Z; Ren H; Du Y; Li Z; Wang C
    Med Sci Monit; 2021 Oct; 27():e931868. PubMed ID: 34599137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.